Investors & Media
Welcome to our investor page
Harnessing the immune system’s full potential to fight human disease.
Biopharmaceutical New Technologies, or BioNTech, is a global, fully-integrated next generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. We have built a broad toolkit across multiple technology platforms, including a diverse range of potentially first-in-class therapeutic approaches. This includes mRNA vaccines, cell and gene therapies, targeted antibodies, small molecule immunomodulators, Ribologicals, and next generation immunomodulators. Our approach has created a robust and diversified product pipeline across infectious disease and oncology, comprised of our first commercial product, COMIRNATY, our COVID-19 vaccine. COMRINATY is the first ever approved mRNA drug product. Our clinical pipeline includes over 19 product candidates in 24 clinical trials, including five randomized Phase 2 clinical trials. We aim for multiple product launches in the next three to five years. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. We believe we are well positioned to develop and commercialize the next generation of immunotherapies with the potential to transform treatment paradigms for many severe diseases.
Press releases (more)
Upcoming events (more)
Data Provided by Refinitiv. Minimum 15 minutes delayed.